Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 5Stomach Neoplasms 4Advanced Gastric Cancer 3Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Respiratory Tract Diseases 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lung Diseases 1Locally Advanced or Metastatic Gastric Adenocarcinoma 1Liver Neoplasms 1Hepatic Metastasis of Colorectal Cancer 1Head and Neck Neoplasms 1Glioma 1Colorectal Neoplasms 1Colorectal Cancer Recurrent 1Biliary Tract Neoplasms 1Advanced Triple Negative Breast Cancer 1Advanced Solid Tumors 1

Interventions

selpercatinib 2repotrectinib 1pralsetinib 1osimertinib 1ficlatuzumab 1cobimetinib 1camrelizumab 1apatinib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Respiratory Tract Diseases × apatinib × Clear all
NCT04133337 2019-10-21

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Sichuan Cancer Hospital and Research Institute

Phase 1/2 Unknown
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡